Cargando…

Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is one of the known oncogenes in urothelial carcinoma. However, the association between HER2 and the prognosis of upper urinary tract urothelial carcinoma (UUTUC) has not yet been fully clarified. The aim of this study was to evaluate HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Gilhyang, Chung, Yul Ri, Kim, Bohyun, Song, Boram, Moon, Kyung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122728/
https://www.ncbi.nlm.nih.gov/pubmed/27725621
http://dx.doi.org/10.4132/jptm.2016.07.12
_version_ 1782469638132596736
author Kim, Gilhyang
Chung, Yul Ri
Kim, Bohyun
Song, Boram
Moon, Kyung Chul
author_facet Kim, Gilhyang
Chung, Yul Ri
Kim, Bohyun
Song, Boram
Moon, Kyung Chul
author_sort Kim, Gilhyang
collection PubMed
description BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is one of the known oncogenes in urothelial carcinoma. However, the association between HER2 and the prognosis of upper urinary tract urothelial carcinoma (UUTUC) has not yet been fully clarified. The aim of this study was to evaluate HER2 expression using the United States Food and Drug Administration (FDA) criteria and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and compare their prognostic significance in UUTUC. METHODS: HER2 expression was evaluated in 144 cases of UUTUC by immunohistochemistry (IHC) using tissue microarrays. We separately analyzed HER2 expression using the FDA and ASCO/CAP criteria. The IHC results were categorized into low (0, 1+) and high (2+, 3+) groups. RESULTS: Using the FDA criteria, 94 cases were negative, 38 cases were 1+, nine cases were 2+, and three cases were 3+. Using the ASCO/CAP criteria, 94 cases were negative, 34 cases were 1+, 13 cases were 2+, and three cases were 3+. Four cases showing 2+ according to the ASCO/CAP criteria were reclassified as 1+ by the FDA criteria. High HER2 expression by both the FDA criteria and ASCO/CAP criteria was significantly associated with International Society of Urological Pathology high grade (p = .001 and p < .001). The high HER2 expression group classified with the FDA criteria showed significantly shorter cancer-specific survival (p = .004), but the HER2 high and low expression groups classified with the ASCO/CAP criteria did not show significant differences (p = .161) in cancer-specific survival. CONCLUSIONS: HER2 high expression groups were significantly associated with shorter cancer-specific survival, and our study revealed that the FDA criteria are more suitable for determining HER2 expression in UUTUC.
format Online
Article
Text
id pubmed-5122728
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Korean Society of Pathologists and the Korean Society for Cytopathology
record_format MEDLINE/PubMed
spelling pubmed-51227282016-12-09 Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma Kim, Gilhyang Chung, Yul Ri Kim, Bohyun Song, Boram Moon, Kyung Chul J Pathol Transl Med Original Article BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is one of the known oncogenes in urothelial carcinoma. However, the association between HER2 and the prognosis of upper urinary tract urothelial carcinoma (UUTUC) has not yet been fully clarified. The aim of this study was to evaluate HER2 expression using the United States Food and Drug Administration (FDA) criteria and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and compare their prognostic significance in UUTUC. METHODS: HER2 expression was evaluated in 144 cases of UUTUC by immunohistochemistry (IHC) using tissue microarrays. We separately analyzed HER2 expression using the FDA and ASCO/CAP criteria. The IHC results were categorized into low (0, 1+) and high (2+, 3+) groups. RESULTS: Using the FDA criteria, 94 cases were negative, 38 cases were 1+, nine cases were 2+, and three cases were 3+. Using the ASCO/CAP criteria, 94 cases were negative, 34 cases were 1+, 13 cases were 2+, and three cases were 3+. Four cases showing 2+ according to the ASCO/CAP criteria were reclassified as 1+ by the FDA criteria. High HER2 expression by both the FDA criteria and ASCO/CAP criteria was significantly associated with International Society of Urological Pathology high grade (p = .001 and p < .001). The high HER2 expression group classified with the FDA criteria showed significantly shorter cancer-specific survival (p = .004), but the HER2 high and low expression groups classified with the ASCO/CAP criteria did not show significant differences (p = .161) in cancer-specific survival. CONCLUSIONS: HER2 high expression groups were significantly associated with shorter cancer-specific survival, and our study revealed that the FDA criteria are more suitable for determining HER2 expression in UUTUC. The Korean Society of Pathologists and the Korean Society for Cytopathology 2016-11 2016-10-10 /pmc/articles/PMC5122728/ /pubmed/27725621 http://dx.doi.org/10.4132/jptm.2016.07.12 Text en © 2016 The Korean Society of Pathologists/The Korean Society for Cytopathology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Gilhyang
Chung, Yul Ri
Kim, Bohyun
Song, Boram
Moon, Kyung Chul
Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
title Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
title_full Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
title_fullStr Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
title_full_unstemmed Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
title_short Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
title_sort comparison of the fda and asco/cap criteria for her2 immunohistochemistry in upper urinary tract urothelial carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122728/
https://www.ncbi.nlm.nih.gov/pubmed/27725621
http://dx.doi.org/10.4132/jptm.2016.07.12
work_keys_str_mv AT kimgilhyang comparisonofthefdaandascocapcriteriaforher2immunohistochemistryinupperurinarytracturothelialcarcinoma
AT chungyulri comparisonofthefdaandascocapcriteriaforher2immunohistochemistryinupperurinarytracturothelialcarcinoma
AT kimbohyun comparisonofthefdaandascocapcriteriaforher2immunohistochemistryinupperurinarytracturothelialcarcinoma
AT songboram comparisonofthefdaandascocapcriteriaforher2immunohistochemistryinupperurinarytracturothelialcarcinoma
AT moonkyungchul comparisonofthefdaandascocapcriteriaforher2immunohistochemistryinupperurinarytracturothelialcarcinoma